Neurogene Inc.
Neurogene Inc. (NGNE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NGNE · as of Jun 9, 2026
Key Statistics
Explore Neurogene Inc. Data
ngne stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 83.3%
The NGNE analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $69.50, representing +143.01% upside from the current price of $28.60.
Competitors & Peers
ngne competitorsNGNE
ADCT
ALMS
AUTL
BNTC
FULCStock Performance
Full HistoryAbout Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently fe…
what is neurogene inc. · ngne stock overview · neurogene inc. company profile · who is neurogene inc. ceo · ngne NASDAQ · neurogene inc. headquarters · neurogene inc. business segments
About Stock Overview & Key Data
Neurogene Inc. (NGNE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 7, 2014. As of the latest trading session, NGNE stock price is $28.60, with a market capitalization of $451.9M. The stock has returned +40.73% over the past 12 months and +36.02% year-to-date.
According to 6 Wall Street analysts, the consensus rating for Neurogene Inc. stock is Buy, with an average 12-month price target of $69.50. In fiscal year 2025, Neurogene Inc. reported revenue of — and net income of -$90.4M. For detailed data — including Neurogene Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Neurogene Inc. (NGNE) stock price is $28.60. The stock is traded on NASDAQ under the ticker symbol NGNE. The 52-week range is $14.65 – $37.27.